- Home
- BEAT vs IKNA Comparison
BEAT vs IKNA Comparison
Compare BEAT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- IKNA
- Stock Information
- Founded
- BEAT 2015
- IKNA 2016
- Country
- BEAT United States
- IKNA United States
- Employees
- BEAT N/A
- IKNA N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- IKNA Health Care
- Exchange
- BEAT Nasdaq
- IKNA Nasdaq
- Market Cap
- BEAT 55.6M
- IKNA 61.8M
- IPO Year
- BEAT 2021
- IKNA 2021
- Fundamental
- Price
- BEAT $1.81
- IKNA $1.08
- Analyst Decision
- BEAT Buy
- IKNA Buy
- Analyst Count
- BEAT 1
- IKNA 2
- Target Price
- BEAT $8.00
- IKNA $3.00
- AVG Volume (30 Days)
- BEAT 55.5K
- IKNA 95.3K
- Earning Date
- BEAT 05-13-2025
- IKNA 05-20-2025
- Dividend Yield
- BEAT N/A
- IKNA N/A
- EPS Growth
- BEAT N/A
- IKNA N/A
- EPS
- BEAT N/A
- IKNA N/A
- Revenue
- BEAT N/A
- IKNA N/A
- Revenue This Year
- BEAT N/A
- IKNA N/A
- Revenue Next Year
- BEAT N/A
- IKNA N/A
- P/E Ratio
- BEAT N/A
- IKNA N/A
- Revenue Growth
- BEAT N/A
- IKNA N/A
- 52 Week Low
- BEAT $1.45
- IKNA $0.97
- 52 Week High
- BEAT $3.48
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- BEAT 49.82
- IKNA 37.62
- Support Level
- BEAT $1.78
- IKNA $1.22
- Resistance Level
- BEAT $1.91
- IKNA $1.29
- Average True Range (ATR)
- BEAT 0.15
- IKNA 0.09
- MACD
- BEAT 0.02
- IKNA -0.01
- Stochastic Oscillator
- BEAT 44.67
- IKNA 1.75
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.